AU2021237566A1 - Anti-glycan antibodies and uses thereof - Google Patents

Anti-glycan antibodies and uses thereof Download PDF

Info

Publication number
AU2021237566A1
AU2021237566A1 AU2021237566A AU2021237566A AU2021237566A1 AU 2021237566 A1 AU2021237566 A1 AU 2021237566A1 AU 2021237566 A AU2021237566 A AU 2021237566A AU 2021237566 A AU2021237566 A AU 2021237566A AU 2021237566 A1 AU2021237566 A1 AU 2021237566A1
Authority
AU
Australia
Prior art keywords
seq
antibody
sequence
antigen
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021237566A
Other languages
English (en)
Inventor
Jennifer Cheng
Tony Liang
Leonard Presta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ptm Therapeutics Inc
Original Assignee
Ptm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptm Therapeutics Inc filed Critical Ptm Therapeutics Inc
Publication of AU2021237566A1 publication Critical patent/AU2021237566A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2021237566A 2020-03-17 2021-03-16 Anti-glycan antibodies and uses thereof Pending AU2021237566A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062990927P 2020-03-17 2020-03-17
US62/990,927 2020-03-17
US202063037374P 2020-06-10 2020-06-10
US63/037,374 2020-06-10
US202063074956P 2020-09-04 2020-09-04
US63/074,956 2020-09-04
PCT/US2021/022627 WO2021188591A1 (en) 2020-03-17 2021-03-16 Anti-glycan antibodies and uses thereof

Publications (1)

Publication Number Publication Date
AU2021237566A1 true AU2021237566A1 (en) 2022-09-29

Family

ID=75581605

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021237566A Pending AU2021237566A1 (en) 2020-03-17 2021-03-16 Anti-glycan antibodies and uses thereof

Country Status (8)

Country Link
US (3) US11230608B2 (https=)
EP (1) EP4121460A1 (https=)
JP (2) JP2023518228A (https=)
KR (1) KR20220155333A (https=)
CN (1) CN115698082A (https=)
AU (1) AU2021237566A1 (https=)
CA (1) CA3170434A1 (https=)
WO (1) WO2021188591A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133452A1 (en) * 2022-01-06 2023-07-13 PTM Therapeutics, Inc. Methods of treating solid tumors and compositions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2013078425A1 (en) * 2011-11-22 2013-05-30 University Of Maryland, Baltimore Lambodies with high affinity and selectivity for glycans and uses therefor

Also Published As

Publication number Publication date
US20220340683A1 (en) 2022-10-27
US20210292432A1 (en) 2021-09-23
KR20220155333A (ko) 2022-11-22
JP2023518228A (ja) 2023-04-28
WO2021188591A1 (en) 2021-09-23
CN115698082A (zh) 2023-02-03
CA3170434A1 (en) 2021-09-23
EP4121460A1 (en) 2023-01-25
US11230608B2 (en) 2022-01-25
US20250034276A1 (en) 2025-01-30
JP2026031937A (ja) 2026-02-25

Similar Documents

Publication Publication Date Title
US12122838B2 (en) Humanized anti-CCR7 receptor antibodies
KR102629294B1 (ko) 자가면역 질환을 치료하기 위한 항-ifnar1 항체
BR112020015479A2 (pt) Anticorpos anticlaudina 18.2 e usos dos mesmos
JP7784511B2 (ja) 抗ネクチン－４抗体、それを含むコンジュゲート、及びその適用
US20240117030A1 (en) Multispecific antibodies and uses thereof
TW201902915A (zh) 針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途
JP2026050358A (ja) 治療用抗ｃｄ４０リガンド抗体
JP2022104998A (ja) アミロイド沈着疾患を治療するための方法および組成物
JP2021500916A (ja) 抗ｔｉｍ−３抗体及びその使用
JP2021513324A (ja) 自己免疫疾患およびがんを治療するための抗ｃｘｃｌ１３抗体
WO2011031657A1 (en) Use of an anti-il6 antibody to decrease hepcidin in cancer patients
JP2026031937A (ja) 抗グリカン抗体及びそれらの使用
US12600778B2 (en) Rage antibodies, fragments and uses thereof
US12180274B2 (en) Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
KR20240046502A (ko) 섬유성 질환 치료에 있어서 알파-에놀라제 길항제의 이용
WO2025042888A1 (en) Methods of treating digestive diseases and compositions thereof
US20170137523A1 (en) Therapy for gist
CN120513101A (zh) 抗pvrig/抗tigit双特异性抗体在治疗恶性肿瘤中的用途
TW202444410A (zh) 一種治療系統性紅斑狼瘡的方法
US20210324086A1 (en) Anti-galectin-9 antibody and methods of use thereof
HK1255020A1 (en) Humanized anti-ccr7 receptor antibodies
HK1255020B (en) Humanized anti-ccr7 receptor antibodies